12890_2017_523_MOESM11_ESM.pptx (190.93 kB)
Additional file 11: of Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosisâan interim analysis of results from a prospective, single-center, randomized, parallel-group study
presentation
posted on 2017-12-13, 05:00 authored by Yosuke Tanaka, Mitsunori Hino, Akihiko GemmaFigure ADL. Comparison of changes in mMRC between drug-treated and untreated patients with borderline or less severe PH; Comparison of changes in TMET between drug-treated and untreated patients with borderline PH or less severe PH. (PPTX 190Â kb)